Citrullinated Histone H3 and Procalcitonin as Biomarkers for Diagnosing and Predicting Outcomes in Septic Shock
-
By
-
Nadia Mostafa Mohamed
-
Iman Hussein Shehata
-
Amr Hosny Hamza
-
Nermeen M. A. Abdallah
-
March 2, 2026
-
Clinical Scorecard: Citrullinated Histone H3 and Procalcitonin as Biomarkers for Diagnosing and Predicting Outcomes in Septic Shock
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Hospitalized adult patients in intensive care units (ICUs) with septic and non-septic shock, including those requiring vasopressors. |
| Care Setting | |
Key Highlights
- Procalcitonin (PCT) and other markers have limited specificity for sepsis compared to CitH3.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Regularly monitor CitH3 and other biomarkers to evaluate treatment response and adjust management accordingly.
Risks
Patient & Prescribing Data
Citrullinated histones may indicate the need for aggressive management in septic shock, including potential vasopressor initiation.
Clinical Best Practices
- Implement early recognition protocols for septic shock.
- Utilize a combination of biomarkers for comprehensive assessment.
- Ensure timely initiation of vasopressors and fluid resuscitation.
- Encourage interdisciplinary collaboration in managing septic shock.
References
